Capital Advisors Inc. OK Purchases 17,032 Shares of Pfizer Inc. (NYSE:PFE)

Capital Advisors Inc. OK raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 1.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,413,472 shares of the biopharmaceutical company's stock after buying an additional 17,032 shares during the quarter. Capital Advisors Inc. OK's holdings in Pfizer were worth $35,817,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of PFE. Envestnet Asset Management Inc. lifted its holdings in shares of Pfizer by 13.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 10,402,113 shares of the biopharmaceutical company's stock worth $263,590,000 after purchasing an additional 1,231,296 shares in the last quarter. Hexagon Capital Partners LLC lifted its holdings in shares of Pfizer by 4.3% in the 1st quarter. Hexagon Capital Partners LLC now owns 55,730 shares of the biopharmaceutical company's stock worth $1,412,000 after purchasing an additional 2,307 shares in the last quarter. Investor s Fiduciary Advisor Network LLC lifted its holdings in shares of Pfizer by 16.5% in the 1st quarter. Investor s Fiduciary Advisor Network LLC now owns 29,207 shares of the biopharmaceutical company's stock worth $740,000 after purchasing an additional 4,141 shares in the last quarter. Tradewinds LLC. lifted its holdings in shares of Pfizer by 21.8% in the 1st quarter. Tradewinds LLC. now owns 11,423 shares of the biopharmaceutical company's stock worth $289,000 after purchasing an additional 2,046 shares in the last quarter. Finally, Meridian Investment Counsel Inc. lifted its holdings in shares of Pfizer by 7.2% in the 1st quarter. Meridian Investment Counsel Inc. now owns 69,874 shares of the biopharmaceutical company's stock worth $1,771,000 after purchasing an additional 4,717 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. HSBC dropped their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Citigroup raised their price objective on Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. The Goldman Sachs Group raised their price target on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Finally, Leerink Partners reduced their price objective on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Stock Performance

PFE traded up $0.37 during trading hours on Tuesday, hitting $25.61. The stock had a trading volume of 51,253,171 shares, compared to its average volume of 41,798,107. The company's fifty day simple moving average is $23.76 and its 200 day simple moving average is $24.81. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The stock has a market cap of $145.60 billion, a PE ratio of 18.56, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the firm posted $0.82 EPS. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.72%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.